Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success

About this episode

Lavakumar Karyampudi discusses the evolution of academic institutions in supporting early-phase CGT trials.

In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Lavakumar (Kumar) Karyampudi, Senior Director of Cell Therapies at Moffitt Cancer Center, to discuss how academic institutions are evolving to meet the demands of early-phase CGT trials. Kumar shares how Moffitt is building flexible, end-to-end infrastructure that supports the full development cycle – from translational research to GMP manufacturing. Together, they explore how tighter integration between scientists, clinicians, and operational teams can accelerate first-in-human trials, why academic centres play a crucial role in advancing CGTs, and how the right partnerships can extend institutional capabilities. Connect with Kumar: https://www.linkedin.com/in/lavakumar-karyampudi/

People in this episode

Host: Jason C. Foster

Guest: Lavakumar Karyampudi

Topics covered

• cell therapies
• CGT trials
• translational research
• GMP manufacturing
• academic institutions
• partnerships

Keywords

• cell therapies
• CGT
• translational research
• GMP manufacturing
• first-in-human trials
• academic centres
• partnerships

Mentioned in this episode

Organizations: Moffitt Cancer Center

More episodes of Ori Spotlight

• Ken Harris: Why AI and automation are CGT’s next inflection point · January 27, 2026 · 1h 3m
• Joe DePinto: Why advanced therapies need a new delivery model · January 13, 2026 · 1h 5m
• Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy · December 16, 2025 · 56 min
• John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later · December 3, 2025 · 50 min
• Warner Biddle: Building a commercial model for CAR-T in autoimmune care · September 2, 2025 · 41 min
• Henrik Andersen: How smart planning helps CGT scale further, faster · July 15, 2025 · 54 min